$INSP

Kelly Jason P sold $57K of INSP

Kelly Jason P (See Remarks) sold 963 shares of Inspire Medical Systems, Inc. (INSP) at $59.55 on 2026-08-07.

Original reporting
SEC EDGAR · Kelly Jason P
Published Aug 11, 2026, 11:13 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 11:13 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$INSP
Neutral
medium confidence
Mentioned
$INSP
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INSPNeutralLow
01

Why it matters

The disclosed open-market sale can be used as a sentiment datapoint, but it does not introduce new operational or financial information about INSP.

02

Market read

Traders may note insider selling, but without accompanying fundamental news, the event is unlikely to drive a major repricing.

03

What to watch

The article does not state motivations, total compensation context, or whether other insiders sold/bought around the same time, limiting inference from one transaction.

Relevance 3/10Novelty 3/10Timing: Form 4 filed 2026-08-11, covering a sale dated 2026-08-07.

Background

The article is a SEC Form 4 insider transaction disclosure for Inspire Medical Systems, Inc.

Company-level read

Ticker impact

$INSPNeutralMedium confidence
Context

Inspire Medical Systems insider Kelly Jason P sold 963 shares at $59.55 on 2026-08-07, per a Form 4 filed 2026-08-11.

Expected impact

Low likelihood of a sustained price move solely from this sale; any impact is likely limited to short-term sentiment.

Evidence & confidence

The filing discloses transaction size, price, and post-sale holdings, but provides no new company fundamentals, guidance, or legal/regulatory developments.

Market effects

Minimal, as this is a single-insider transaction without sector-wide signals.

None indicated.

None indicated.

Counterpoint

Insider sales are often planned for diversification or liquidity needs; the absence of a stated 10b5-1 plan does not necessarily imply negative information.

Key entities

  • Inspire Medical Systems, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Kelly Jason P

    Officer who sold 963 shares at $59.55 on 2026-08-07.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$INSPMedAI 8/10

Inspire Medical Systems (INSP) Q2 2026 Earnings Call Transcript

Inspire Medical Systems (NYSE:INSP) reported Q2 2026 revenue of $200.6M, down 7.6% year over year, citing coding and reimbursement disruptions. Adjusted diluted EPS was $0.14 versus $0.34 a year earlier. Gross margin rose to 85.5%. Full-year revenue guidance was raised to $835M-$875M, with an estimated $40M Q2 and $120M-$130M full-year reimbursement headwind.

$INSPMedAI 8/10

Inspire Medical Systems (INSP) Q2 2026 Earnings Call Transcript

Inspire Medical Systems (INSP) reported Q2 2026 revenue of $200.6 million, down 7.6% year over year, citing coding and reimbursement disruptions. Adjusted diluted EPS was $0.14 versus $0.34 a year earlier. Management raised full-year revenue guidance to $835 million to $875 million and estimated a $40 million Q2 adverse impact, with $120 million to $130 million for the year.

$INSPMedAI 8/10

5 Insightful Analyst Questions From Inspire Medical Systems’s Q2 Earnings Call

Inspire Medical Systems (INSP) reported Q2 results with improved coding clarity and cost discipline, citing outperformance versus Wall Street expectations despite year-on-year revenue decline. Revenue was $200.6M vs $194.7M estimate, adjusted EPS $0.14 vs -$0.25, and adjusted EBITDA $38.9M vs $27.68M. Full-year revenue guidance was raised to $855M and adjusted EPS to $1.25 at the midpoint.

$INSPHighAI 9/10

Why Are Inspire Medical Systems (INSP) Shares Soaring Today

Inspire Medical Systems (INSP) shares rose 18.3% after the company reported a “beat and raise” quarter and announced a restructuring initiative. Revenue was $200.6M vs $194.7M consensus, adjusted EPS was $0.14 vs a $0.25 loss expected, and adjusted EBITDA was $38.9M. Full-year revenue guidance midpoint rose to $855M and adjusted EPS to $1.25. Oppenheimer upgraded to Outperform with an $85 target.

$INSPHighAI 9/10

Inspire Medical Systems Analysts Raise Their Forecasts Following Strong Q2 Results - Inspire Medical Syst

Inspire Medical Systems reported Q2 EPS of 14 cents, versus a consensus loss of 27 cents, and sales of $200.581 million versus $194.671 million. The company raised FY2026 adjusted EPS guidance to $1.05-$1.45 and sales guidance to $835 million-$875 million. Shares rose 14.6% premarket to $59.85, and analysts at Baird and Piper Sandler lifted price targets.